Generic Name:
Daratumumab
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Janssen Canada Inc.
Brand Name:
Darzalex
Project Line:
Reimbursement Review
Project Number:
PC0079-000
NOC Date:
Details
Strength:
100mg/5mL and 400mg/20mL
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
For the treatment of patients with multiple myeloma who 1) have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD); OR 2) have failed or are intolerant to a PI and who have failed or are intolerant to an IMiD
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Janssen Canada Inc.
Submission Date:
Submission Deemed Complete:
Submission Date (Target Date):
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Funding Request:
For the treatment of patients with multiple myeloma who 1) have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD); OR 2) have failed or are intolerant to a PI and who have failed or are intolerant to an IMiD
pERC Meeting:
Final Recommendation Issued: